Project Grant R21CA289216
Award Date
1/1/25
Completion Date
12/31/26
Dollars Obligated
$227K
Federal Agency
National Cancer Institute
Federal Grant Program
93.395
Assistance Type
Project Grant
Place of Performance
Richmond, VA 23219, USA
Similar Awards
This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides $181,448 to Virginia Commonwealth University (VCU) to determine if the oral NLRP3 inflammasome inhibitor dapansutrile can alleviate and prevent chemotherapy-induced peripheral neuropathy (CIPN) in a mouse model. The key objectives are to: 1) assess the effects of dapansutrile after acute and chronic oral administration in mice treated with the chemotherapeutic agents paclitaxel and...
This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides $375,134 to the University of Colorado-Denver to investigate a novel approach to reduce the accumulation of chemotherapeutic nanomedicines in healthy tissues and improve the efficacy of cancer treatment. The key focus is on leveraging the innate immune response of epithelial tightening, mediated by the cytokine IFN-λ, to limit nanoparticle deposition in healthy organs while allowing...
This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides funding of $435,773 to the University of Maryland, Baltimore to develop an engineered prodrug that leverages tumor-associated proteases to selectively deliver a potent cytotoxin into cancer cells. The goal is to create a targeted therapeutic strategy to improve treatment outcomes for metastatic and recurrent solid tumors, including ovarian, lung, and colon cancers. Key elements of the...
This federal Project Grant award from the National Cancer Institute (CFDA 93.395 Cancer Treatment Research) provides $622,329 to Virginia Commonwealth University (VCU) to conduct research aimed at modulating growth, progression, and metastasis in breast cancer by inhibiting the MDA-9 protein. The key products and services to be delivered include: Formulating the PDZ1I small molecule inhibitor of MDA-9 for clinical applications, including developing a novel nanocrystal technology (PDZ1I-nano) and...
This $180,632 federal Project Grant award from the National Cancer Institute under the Cancer Treatment Research program (CFDA 93.395) supports research to discover and validate compounds that can block cancer cell engulfment of mesenchymal stem cells, which has been linked to increased metastatic potential in breast cancer. The two-year project, running from May 2025 to April 2027, will leverage high-throughput microfluidic technology to conduct a comprehensive screening of 2,726 compounds with...
This $769,073 Project Grant awarded by the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) supports research to define and target cancer cell-intrinsic vulnerabilities in renal cell carcinoma. The grant was awarded to the Royal Institution for the Advancement of Learning / McGill Office of Sponsored Research Division, a private university affiliated with McGill University in Montreal, Canada. The research will be conducted from August 1, 2024...
The National Cancer Institute (NCI) awarded a $396,061 Project Grant under the Cancer Treatment Research program (CFDA 93.395) to the University of Missouri at Kansas City (UMKC). The grant, running from August 2024 to July 2026, aims to assess the potential therapeutic efficacy of newly synthesized boron-based inhibitors of the Hypoxia-Inducible Factor (HIF) pathway as a treatment strategy for renal cell carcinoma (RCC). Specifically, the project will (1) determine the...
The National Cancer Institute (NCI) awarded a Project Grant (CFDA 93.395 - Cancer Treatment Research) to The Washington University in the amount of $849,371 on August 2, 2024. The grant, titled "Hijacking Post-Translational Arginylation for Targeted Protein Degradation," aims to develop innovative methods for targeted protein degradation using the arginylation pathway. Key project activities include: 1) Applying computational techniques to identify potential ATE1 binding compounds,...
This federal Project Grant award from the National Institute of Diabetes and Digestive and Kidney Diseases (CFDA 93.847 - Diabetes, Digestive, and Kidney Diseases Extramural Research) is providing $645,599 to the University of Pittsburgh to conduct research on using dicarboxylic acid (DCA) therapy to prevent and treat acute kidney injury (AKI) and prevent the progression to chronic kidney disease (CKD). The research aims to demonstrate that supplementing the diet with medium-chain dicarboxylic...
This Project Grant award of $628,987 from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847) supports research to understand how increasing mitochondrial superoxide dismutation in renal tubular cells can reduce cisplatin-induced kidney injury and promote renal repair. The key objectives are to: 1) determine how tubular mitochondrial superoxide interactions with electron...